Nature Medicine Publishes ASPEN-06 Data: Evorpacept Shows 40.3% ORR in HER2+ Gastric Cancer
ALXO sits 24% above its 52-week low of $1.05.
Summary
ALX Oncology announced publication of ASPEN-06 Phase 2 data in Nature Medicine, showing evorpacept plus TRP achieved 40.3% ORR vs 26.6% for control in HER2-positive gastric cancer. In patients with retained HER2 and high CD47 expression, ORR jumped to 63.6% vs 23.1%, with median PFS of 19.5 vs 7.0 months. The company also disclosed it will not pursue a U.S. registrational path in gastric cancer and will seek partnerships, while advancing the ASPEN-09-Breast trial with topline data expected mid-2027. This is the first detailed disclosure of these results and the strategic decision, following a narrower Q2 loss reported in August. The biomarker-driven data strengthens the case for evorpacept in breast cancer, but the lack of a registrational path in gastric cancer tempers the near-term commercial outlook.
At the time of this announcement, ALXO was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $181.1M. The 52-week trading range was $1.05 to $2.66. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.